Please assess the completion status of the following clinical trial:

Trial Title: 18-Month Study of Memory Effects of Curcumin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Agreement to participate in the 18-month double-blind, placebo-controlled clinical trial of curcumin.~2. Diagnostic criteria for mild cognitive impairment (MCI) or any age related memory decline according to standard criteria (Petersen et al, 2001; Crook et al, 1986).~3. Age 50 to 90 years.~4. No significant cerebrovascular disease: modified Ischemic Score of \< 4 (Rosen et al, 1980).~5. Adequate visual and auditory acuity to allow neuropsychological testing.~6. Screening laboratory tests and EKG without significant abnormalities that might interfere with the study.~Exclusion Criteria~1. Diagnosis of probable Alzheimer's disease (AD) or any other dementia (e.g., vascular, Lewy body, frontotemporal) (McKhann et al, 1984).~2. Evidence of other neurological or physical illness that can produce cognitive deterioration. Volunteers with a history of stroke, TIA, carotid bruits, or lacunes on MRI scans will be excluded.~3. Inability to undergo MRI.~4. Evidence of Parkinson's disease as determined by the motor examination (items 18-31) of the Unified Parkinson's Disease Rating Scale (Fahn et al, 1987).~5. History of myocardial infarction within the previous year, or unstable cardiac disease.~6. Uncontrolled hypertension (systolic BP \> 170 or diastolic BP \> 100).~7. History of significant liver disease, clinically-significant pulmonary disease, diabetes, or cancer.~8. Current diagnosis of any major psychiatric disorder according to the DSM-IV TR criteria (APA, 2000).~9. Current diagnosis or history of alcoholism or substance addiction.~10. Regular use of any medication that may affect cognitive functioning including: centrally active beta-blockers, narcotics, Clonidine, anti-Parkinsonian medications, antipsychotics, benzodiazepines, systemic corticosteroids, medications with significant cholinergic or anticholinergic effects, anti-convulsants, or Warfarin. Occasional chloral hydrate use will be allowed, but discouraged, for insomnia.~11. Use of more than one multivitamin per day. Vitamins other than the standard multivitamin supplement will not be allowed.~12. Use of medications known to affect FDDNP-PET binding (e.g., ibuprofen, naproxen).~13. Use of more than one daily baby aspirin (81mg) and/or use of any medication containing curcumin.~14. Use of cognitive enhancing supplements (e.g. Ginkgo biloba).~15. Use of any investigational drugs within the previous month or longer, depending on drug half-life.~16. Pregnancy.~17. HIV infection.~18. Evidence of vasogenic edema; specifically, evidence of more than 4 cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as possible or definite) or a single area of superficial siderosis), or evidence of a prior macrohemorrhage at screening or baseline.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Curcumin (Type: ACTIVE_COMPARATOR): Theracurmin (180mg/day)
- Placebo (Type: PLACEBO_COMPARATOR): Sugar Pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete